Simply Wall St.2d agoneutral
Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still UndervaluedNews
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
105last 24h
3125last 7d
510● bullish (7d)
311● bearish (7d)
227publishers
GuruFocus.com2d agoneutral
Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher GuidanceSimply Wall St.2d agobullish
Halozyme Stock Jumps On Strong Earnings But Guidance Reset Raises QuestionsGuruFocus.com2d agoneutral
Halozyme Therapeutics Inc (HALO) (Q3 2026) Earnings Call Highlights: Record Revenue, Raised ...MT Newswires3d agoneutral
Halozyme Therapeutics Q3 Adjusted Earnings, Revenue Rise; 2026 Guidance LiftedPR Newswire3d agoneutral
HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCEStockStory85d agoneutral
The Top 5 Analyst Questions From Halozyme Therapeutics’s Q2 Earnings CallStockStory89d agobullish
HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded GuidanceSimply Wall St.92d agobullish
Is Halozyme Therapeutics (HALO) Fairly Valued As Earnings Beat And Guidance Rise?GuruFocus.com93d agoneutral
Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ...